H1710 / Shenzhen Hepalink - LARVOL DELTA

GWAS-Based Mining of Candidate Genes for Low-Nitrogen Tolerance in Maize. (PubMed, Int J Mol Sci) - "Furthermore, several inbred lines (H1710, 23N272, and 23N41) demonstrating superior low-nitrogen tolerance were identified. The primary subsequent focus in future research for these genetic materials will be their utilization to breed new cultivars with enhanced nitrogen use efficiency."

Journal

Gene Mapping and Genetic Analysis of Maize Resistance to Stalk Rot. (PubMed, Int J Mol Sci) - "In this study, the highly resistant maize inbred line H1710 and highly susceptible inbred line Huangzaosi were used to construct segregating populations through hybridization, backcrossing, and other methods...Furthermore, KASP molecular markers designed for the candidate region precisely localized two candidate genes, Zm00001eb260120 and Zm00001eb260260, which were considered to be the most likely genes mediating stalk rot resistance. The study findings lay a theoretical foundation for analyzing the molecular basis of maize resistance to Fusarium stalk rot and cloning the relevant resistance genes."

Journal

A Clinical Study Evaluating H1710 for Injection in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Shenzhen Hepalink Pharmaceutical Group Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Solid Tumor

H1710 INJECTION HAS ENROLLED THE FIRST SUBJECT AND COMPLETED THE FIRST DOSING IN THE PHASE 1 CLINICAL TRIAL (HKEXnews) - "The board of directors of the Company (the 'Board') is pleased to announce that the Company has recently completed the enrollment of the first subject and the first dosing in the phase I clinical trial of its independently developed innovative candidate drug, the H1710 injection ('H1710')....This clinical trial is an open-label, dose-escalation Phase Ia clinical study, evaluating the safety, tolerability and preliminary anti-tumor activity of H1710 in patients with advanced solid tumors. This is the first in-human trial for H1710, which is planned to be conducted at three research centers, with an estimated enrollment of about 36 patients."

Trial status • Solid Tumor

A Clinical Study Evaluating H1710 for Injection in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=36 | Not yet recruiting | Sponsor: Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

New P1 trial • Solid Tumor

Hepalink’s independently developed innovative drug candidate H1710 has been approved for IND for the treatment of advanced solid tumors [Google translation] (Hepalink Press Release) - "Shenzhen Hepalink Pharmaceuticals Group Co., Ltd...announced that the Company's independently developed innovative drug candidate H1710 targeting heparanase (HPA) has obtained the approval of the China National Medical Products Administration (NMPA) for the new drug clinical trial application (IND), and will soon conduct a Phase I clinical trial for advanced solid tumors in China...The company's preclinical studies have shown that H1710 exhibits anti-tumor pharmacological activity by inhibiting the activity and expression of heparanase, and exhibits significant tumor inhibition in a variety of tumor animal models. To date, there are no similar products with the same molecular mechanism on the market worldwide."

New trial • Preclinical • Solid Tumor